Project: Selection and development of a therapeutic antibody against drug-resistant Klebsiella pneumoniae

Acronym SPARKLE (Reference Number: 11302)
Duration 01/11/2017
Project Topic The consortium will develop and perform the preclinical validation of an innovative therapeutic strategy against antibiotic-resistant Klebsiella pneumoniae (ARKP) infections. Klebsiella pneumoniae (KP) is a common hospital-acquired pathogen for which, due to resistance, treatment options are very limited. The therapy is based on a therapeutic monoclonal antibody (mAb) that specifically targets ARKP. Upon completion of the project, the mAb product will be ready for further clinical development.
Network Eurostars 2
Call Eurostars Cut-Off 7

Project partner

Number Name Role Country
1 Evaxion Biotech Coordinator Denmark
2 MAB Discovery Partner Germany
3 Pepscan Therapeutics BV Partner Netherlands
4 Preclin Biosystems AG Partner Switzerland
5 Karolinska Institute Partner Sweden